Imaging biomarker roadmap for cancer studies

Autor: Gary Cook, Geoff J M Parker, Gordon C Jayson, Judith E. Adams, Andrew J. I. Jones, Edward F. Jackson, Paul S. Tofts, James P B O'Connor, Laurence P. Clarke, Nathalie Lassau, Sandra Collette, Bruno Morgan, Andrew C. Peet, Lalitha K. Shankar, Fiona J. Gilbert, Ricky A. Sharma, Kevin M. Brindle, Ting-Yim Lee, Sarah E. Bohndiek, Hugo J.W.L. Aerts, Ferdia A. Gallagher, John R. Griffiths, Andrew R. Reynolds, Martin O. Leach, Anwar R. Padhani, John Dickson, Steve Halligan, Ross J. Maxwell, Shonit Punwani, Eric O. Aboagye, John C. Waterton, Adrian L. Harris, Simon Walker-Samuel, Prakash Manoharan, Nandita M. deSouza, James Wason, Stuart A. Taylor, David L. Buckley, Caroline Dive, David J. Hawkes, Thomas E. Yankeelov, Brian Hutton, Gillian M. Tozer, Thomas L. Chenevert, Mike Partridge, Sigrid Stroobants, Dow-Mu Koh, Edward Leen, Sally F. Barrington, Erich P. Huang, Lisa M. McShane, Denis Lacombe, Kaye J. Williams, Ambros J. Beer, Corinne Faivre-Finn, Daniel C. Sullivan, Ashley M. Groves, Kenneth A. Miles, Otto S. Hoekstra, Robert J. Gillies, J. Michael Brady, Simon P. Robinson, Gina Brown, Vicky Goh, Tony Ng, Jeffrey L. Evelhoch, Mark F. Lythgoe, Yan Liu, Ronald Boellaard, Alan Jackson, Dmitry Soloviev, Marcel van Herk, Paul Workman, Arvind P. Pathak, Steve Morris, Jason S. Lewis, Philippe Lambin
Přispěvatelé: Medical Research Council (MRC), Cancer Research UK, Engineering & Physical Science Research Council (EPSRC), US Army (US), National Institute for Health Research, Scottish Power Foundation, Pfizer Limited, Commission of the European Communities, Imperial College Healthcare NHS Trust- BRC Funding, GlaxoSmithKline Services Unlimited, Bohndiek, Sarah [0000-0003-0371-8635], Gallagher, Ferdia [0000-0003-4784-5230], Gilbert, Fiona [0000-0002-0124-9962], Griffiths, John [0000-0001-7369-6836], Morris, Stephen [0000-0002-5828-3563], Wason, James [0000-0002-4691-126X], Brindle, Kevin [0000-0003-3883-6287], Apollo - University of Cambridge Repository, Guided Treatment in Optimal Selected Cancer Patients (GUTS), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Biomedical Engineering and Physics
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Research design
medicine.medical_specialty
Pathology
Imaging biomarker
Standardization
Cost-Benefit Analysis
CELL LUNG-CANCER
Clinical Decision-Making
MEDLINE
HIGH FAMILIAL RISK
Article
030218 nuclear medicine & medical imaging
03 medical and health sciences
CONTRAST-ENHANCED MRI
0302 clinical medicine
Breast cancer
Folic Acid
POSITRON-EMISSION-TOMOGRAPHY
Fluorodeoxyglucose F18
Neoplasms
Biomarkers
Tumor
Medicine
BREAST-CANCER
Humans
Medical physics
GROUP DEVELOPMENTAL PATHWAY
DRUG DEVELOPMENT
Selection Bias
Accreditation
business.industry
Reproducibility of Results
Organotechnetium Compounds
medicine.disease
Prognosis
3. Good health
Clinical trial
Oncology
Drug development
Research Design
ADVANCED SOLID TUMORS
030220 oncology & carcinogenesis
Positron-Emission Tomography
Human medicine
Radiopharmaceuticals
business
SURROGATE END-POINTS
CLINICAL-TRIALS
Biomarkers
Zdroj: O'Connor, J P B, Aboagye, E O, Adams, J E, Aerts, H J W L, Barrington, S F, Beer, A J, Boellaard, R, Bohndiek, S E, Brady, M, Brown, G, Buckley, D L, Chenevert, T L, Clarke, L P, Collette, S, Cook, G J, deSouza, N M, Dickson, J C, Dive, C, Evelhoch, J L, Faivre-Finn, C, Gallagher, F A, Gilbert, F J, Gillies, R J, Goh, V, Griffiths, J R, Groves, A M, Halligan, S, Harris, A L, Hawkes, D J, Hoekstra, O S, Huang, E P, Hutton, B F, Jackson, E F, Jayson, G C, Jones, A, Koh, D-M, Lacombe, D, Lambin, P, Lassau, N, Leach, M O, Lee, T-Y, Leen, E L, Lewis, J S, Liu, Y, Lythgoe, M F, Manoharan, P, Maxwell, R J, Miles, K A, Morgan, B, Morris, S, Ng, T, Padhani, A R, Parker, G J M, Partridge, M, Pathak, A P, Peet, A C, Punwani, S, Reynolds, A R, Robinson, S P, Shankar, L K, Sharma, R A, Soloviev, D, Stroobants, S, Sullivan, D C, Taylor, S A, Tofts, P S, Tozer, G M, van Herk, M, Walker-Samuel, S, Wason, J, Williams, K J, Workman, P, Yankeelov, T E, Brindle, K M, McShane, L M, Jackson, A & Waterton, J C 2016, ' Imaging biomarker roadmap for cancer studies ', Nature Reviews Clinical Oncology . https://doi.org/10.1038/nrclinonc.2016.162
Nature reviews. Clinical oncology
O'Connor, J P B, Aboagye, E O, Adams, J E, Aerts, H J W L, Barrington, S F, Beer, A J, Boellaard, R, Bohndiek, S E, Brady, M, Brown, G, Buckley, D L, Chenevert, T L, Clarke, L P, Collette, S, Cook, G J, deSouza, N M, Dickson, J C, Dive, C, Evelhoch, J L, Faivre-Finn, C, Gallagher, F A, Gilbert, F J, Gillies, R J, Goh, V, Griffiths, J R, Groves, A M, Halligan, S, Harris, A L, Hawkes, D J, Hoekstra, O S, Huang, E P, Hutton, B F, Jackson, E F, Jayson, G C, Jones, A, Koh, D-M, Lacombe, D, Lambin, P, Lassau, N, Leach, M O, Lee, T-Y, Leen, E L, Lewis, J S, Liu, Y, Lythgoe, M F, Manoharan, P, Maxwell, R J, Miles, K A, Morgan, B, Morris, S, Ng, T, Padhani, A R, Parker, G J M, Partridge, M, Pathak, A P, Peet, A C, Punwani, S, Reynolds, A R, Robinson, S P, Shankar, L K, Sharma, R A, Soloviev, D, Stroobants, S, Sullivan, D C, Taylor, S A, Tofts, P S, Tozer, G M, van Herk, M, Walker-Samuel, S, Wason, J, Williams, K J, Workman, P, Yankeelov, T E, Brindle, K M, McShane, L M, Jackson, A & Waterton, J C 2017, ' Imaging biomarker roadmap for cancer studies ', Nature Reviews Clinical Oncology, vol. 14, no. 3, pp. 169-186 . https://doi.org/10.1038/nrclinonc.2016.162
Nature Reviews Clinical Oncology
Nature Reviews Clinical Oncology, 14(3), 169-186. Nature Publishing Group
O'Connor, J P B, Aboagye, E O, Adams, J E, Aerts, H J W L, Barrington, S F, Beer, A J, Boellaard, R, Bohndiek, S E, Brady, M, Brown, G, Buckley, D L, Chenevert, T L, Clarke, L P, Collette, S, Cook, G J, deSouza, N M, Dickson, J C, Dive, C, Evelhoch, J L, Faivre-Finn, C, Gallagher, F A, Gilbert, F J, Gillies, R J, Goh, V, Griffiths, J R, Groves, A M, Halligan, S, Harris, A L, Hawkes, D J, Hoekstra, O S, Huang, E P, Hutton, B F, Jackson, E F, Jayson, G C, Jones, A, Koh, D M, Lacombe, D, Lambin, P, Lassau, N, Leach, M O, Lee, T Y, Leen, E L, Lewis, J S, Liu, Y, Lythgoe, M F, Manoharan, P, Maxwell, R J, Miles, K A, Morgan, B, Morris, S, Ng, T, Padhani, A R, Parker, G J M, Partridge, M, Pathak, A P, Peet, A C, Punwani, S, Reynolds, A R, Robinson, S P, Shankar, L K, Sharma, R A, Soloviev, D, Stroobants, S, Sullivan, D C, Taylor, S A, Tofts, P S, Tozer, G M, van Herk, M, Walker-Samuel, S, Wason, J, Williams, K, Workman, P, Yankeelov, T E, Brindle, K M, McShane, L M, Jackson, A & Waterton, J C 2017, ' Imaging biomarker roadmap for cancer studies ', Nature Reviews Clinical Oncology, vol. 14, no. 3, pp. 169-186 . https://doi.org/10.1038/nrclinonc.2016.162
Nature reviews. Clinical oncology, 14(3), 169-186. Nature Publishing Group
ISSN: 1759-4774
DOI: 10.1038/nrclinonc.2016.162
Popis: Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
Databáze: OpenAIRE
Externí odkaz: